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Background: The cellular and molecular mechanisms that mediate interactions between tumour cells and the
surrounding bone stroma are to date largely undetermined in prostate cancer (PCa) progression. The purpose of this
study was to evaluate the role of alpha 6 and beta 1 integrin subunits in mediating tumour-stromal interactions.
Methods: Utilising 3D in vitro assays we evaluated and compared 1. Monocultures of prostate metastatic PC3, bone
stromal derived HS5 and prostate epithelial RWPE-1 cells and 2. Tumour-stromal co-cultures (PC3 + HS5) to ascertain
changes in cellular phenotype, function and expression of metastatic markers.
Results: In comparison to 3D monocultures of PC3 or HS5 cells, when cultured together, these cells displayed
up-regulated invasive and proliferative qualities, along with altered expression of epithelial-to-mesenchymal and
chemokine protein constituents implicated in metastatic dissemination. When co-cultured, HS5 cells were found to
re-express N-Cadherin and chemokine receptor CXCR7. Alterations in N-Cadherin expression were found to be
mediated by soluble factors secreted by PC3 tumour cells, while chemokine receptor re-expression was dependent
on direct cell-cell interactions. We have also shown that integrins beta 1 and alpha 6 play an integral role in
maintaining cell homeostasis and mediating expression of E-Cadherin, N-Cadherin and vimentin, in addition to
chemokine receptor CXCR7.
Conclusions: Collectively our results suggest that both PC3 and HS5 cells provide a “protective” and reciprocal
milieu that promotes tumour growth. As such 3D co-cultures may serve as a more complex and valid biological
model in the drug discovery pipeline.
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IntegrinsIntroduction
It is well established that the reciprocal interaction of
tumour cells with local bone stroma at the metastatic site
plays a critical role in metastatic dissemination in prostate
cancer (PCa) [1,2]. To-date however, studies have not yet
addressed how at the cellular level, these tumour-stromal
interactions affect important protein constituents impli-
cated in metastatic dissemination including epithelial-
to-mesenchymal transition (EMT) proteins and chemokine
receptor expression. Here we have undertaken direct com-
parisons between 3D monocultures and tumour-stromal* Correspondence: v.avery@griffith.edu.au
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reproduction in any medium, provided the orco-cultures, temporally comparing their expression of
tumourigenic markers. In addition, we have established
a role for both β1 and α6 integrin subunits in mediating
tumour-stromal interactions.
Recently the evaluation of tumour-stromal cell interac-
tions has been undertaken using a 3D co-culture model.
The importance of studying tumours in 3D has been
previously described [3,4]. Using these models, studies
have shown that when cultured with PCa cells, stromal
cells express increased levels of extracellular matrix (versican
and tenascin) and chemokine (CCL5, CXCL5, and CXCL16)
genes [5], consistent with metastatic clinical tissue samples.
Highlighting the reciprocal nature of tumour-stromal inter-
actions, others have shown that when PCa LNCaP cells areLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Windus et al. Molecular Cancer 2013, 12:112 Page 2 of 19
http://www.molecular-cancer.com/content/12/1/112co-cultured with human prostate or bone stromal cells
in 3D conditions, permanent genetic, morphological and
behavioural changes are seen in LNCaP cells [6] indicative
of a more invasive phenotype.
An important first step in establishing communication
between metastasising cancer cells and surrounding bone
stromal cells is the exit of cancer cells from the vascula-
ture once in the bone marrow. Studies suggest that the
chemokine, CXCL12, plays a role in trafficking PCa cells
to the bone. CXCL12 is expressed by stromal cells in
target organs of PCa metastasis (bone, brain, lymph), but
not in other tissues [7] and its receptors, CXCR4 and
CXCR7, are highly expressed by bone metastatic PCa cells
[8,9]. The direct role CXCR7 may play, once PCa cells have
established contact with surrounding bone stromal cells, is
still unclear. However, growing evidence supports a role for
cooperative signalling between integrins and CXCRs in
establishing cross-talk between tumour and stromal cells,
and colonisation of tumour cells to the bone [10].
Tumour cells localize to bone regions through integrin-
mediated contacts with the extracellular matrix (ECM)
and stromal cells. Heavily implicated in PCa bone metas-
tases development and progression is the integrin β1 sub-
unit [11-13]. Expression of α5β1 and α2β1 on PCa cells
has been reported to facilitate interactions with bone
stromal cells [13] and to actively promote invasion and
adherence of PCa cells to the bone stroma in vitro [12]
and experimental bone metastases in vivo [11]. Similarly
the laminin-binding integrin α6β1 has been shown to
permit extravasation of human prostate cancer cells from
circulation to the bone stroma in vivo [14-16]. While
experimental evidence has clearly shown a direct role
for integrins α5β1 and α2β1 it is not yet clear how α6β1
may then mediate tumour-stromal interactions once the
tumour cells have reached the bone micro-environment.
It is the aim of the current paper to further clarify the
roles α6 and β1 subunits may have in mediating bone
tumour-stromal interactions.
Another important factor that allows PCa cells to infil-
trate surrounding tissues and metastasise is the induction
of EMT. The common feature of EMT is the loss of
E-Cadherin and up-regulation of N-Cadherin and vimentin
[17,18]. Evidence of EMT has been provided in both in vitro
and in vivo models [19-21] with the switch believed to
initiate release and dissemination of cancer cells from
the organ of origin. It has also been suggested that once
disseminated, mesenchymal tumour cells recruited to the
target organ may undergo a reversal from mesenchymal-
to-epithelial transition (MET). Evidence of MET has been
limited to in vitro and xenograft experiments primarily in
breast and bladder cancer [22,23]. From these experiments
it has been suggested that MET of the tumour cells may
not be driven by cell intrinsic mutations but is under the
influence of the pre-metastatic niches in distal organs[24,25]. Surprisingly, few studies have evaluated and vali-
dated the occurrence of EMT/MET in in vivo prostatic
models. To-date one study has confirmed the progressive
nature of EMT in prostate cells during xenograft tumour
formation and metastasis [26]. Consistent with previous
findings in breast cancer, in this prostate model, cancer
cells acquire cellular plasticity and EMT progression
primarily through interactions with the host tumour
micro-environment [26]. Thus in the current study we
further evaluated EMT/MET proteins of interest including
E-Cadherin, N-Cadherin and vimentin.
Here we evaluate and compare both monocultures and
co-cultures of metastatic PC3 cells and bone stromal de-
rived HS5 cells using 3D in vitro models. In comparison
to monocultures, cells in tumour-stromal co-cultures
display alterations in morphology, invasion, proliferation
and expression of chemokine and EMT markers. More-
over, mediation of EMT and chemokine markers by α6β1
integrins is altered in co-cultures when compared to their
monocultured counterparts. Collectively, our results sug-
gest that stromal cells are extremely plastic and together
with metastatic cells can co-operate in a reciprocal manner
to produce an emergent behaviour that is more malignant.
These results may give further insight into the limitations
of specific therapeutics that target tumour cells alone.
Results
Characterisation of tumour-stromal co-culture morphology
To investigate differences in morphological characteris-
tics and cell junction formation between HS5, PC3 and
tumour-stromal co-cultures (HS5 + PC3 and HS5 +DU145),
we used differential inference contrast (DIC) optics, immu-
nostaining and imaging techniques to reconstruct 3D im-
ages from cells grown in 3D cultures. The described 3D
model consists of cells grown as 3D spheroids following
plating on a bed of extracellular matrix, Matrigel. In order
to distinguish HS5, DU145 and PC3 cells in co-culture,
we used a bone marrow stromal cell specific marker,
STRO-1 [27] to visualise HS5 cells. To-date there are no
known tumourigenic specific markers for PC3 or DU145
cells, thus to visualise all cells in culture we used a cyto-
plasmic and nucleic general stain; Cell Mask. We could
then determine that cells negative for STRO-1 but positive
for Cell Mask were tumour cells, while cells that were
both STRO-1 and Cell Mask positive were HS5 cells.
When plated on Matrigel matrix, both stromal and
tumour cells clearly differentiated and formed relevant
multi-cellular structures. In agreement with our previous
findings [4,28], PC3 cells formed irregular shaped clusters
(Figure 1A-A”) with stellate radiating tubular processes
(Figure 1A’; arrowheads). Consistent with metastatic
tumour formation in vivo, a central Z-slice of PC3 cells
stained for F-actin showed no evidence of polarisation or
lumen formation within the centre of the cell mass
Figure 1 Morphology of metastatic PC3 and Bone stromal (HS5) cells in monoculture and co-culture (PC3 + HS5) conditions. (A) Differential
Interference Contrast (DIC) images of PC3 cells. (A’) F-actin staining of a 3D reconstruction of a PC3 spheroid mass. PC3 cells displayed radiating
tubular structures (filled arrowheads). (A”) A central Z-slice of a 3D PC3 mass. (B) DIC images of HS5 cells. (B’) F-actin staining of a 3D reconstruction of
a HS5 spheroid mass. (B”) A central Z-slice of a 3D HS5 mass displaying an absence of cells in the inner region (arrow). (C) DIC images of
a co-cultured cells. (C’) Immunostaining of co-cultures revealed that HS5 (STRO-1) and (C”) PC3 cells (Cell Mask blue; arrows) formed cell-cell contacts.
(D-D’) Immunostaining of co-cultures with HS5 (STRO-1) and DU145 cells (arrows) revealed an absence of cell-cell contacts. (E) Western blot and
densitometric analysis of endogenous expression of α6 and β1 integrin subunits in monocultured HS5 cells and in co-cultures over 9 days. (F-F’)
Immunostaining of endogenous β1 integrin expression on HS5 (STRO-1 positive; green fluorescence) and PC3 (cell mask blue positive; STRO-1 negative)
cells in co-culture. (G) Quantification of the percentage of PC3 and HS5 cells expressing β1 integrin in co-culture. (H-H’) Immunostaining of endogenous
α6 integrin expression on HS5 (STRO-1 positive; green fluorescence) and PC3 (cell mask blue positive; STRO-1 negative) cells in co-culture. i) Quantification
of the percentage of PC3 and HS5 cells expressing α6 integrin in co-culture (**p < 0.01, ***p < 0.001). Error bars denote S.E.M. Scale bars = 40 μm.
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rounded masses marked by a meshwork of interlacing
cells primarily around the outer regions of the mass(Figure 1B’), with a distinct absence of cells in the inner
region (Figure 1B”; arrowhead). These masses clearly
lacked cell polarisation and acinar formation.
Windus et al. Molecular Cancer 2013, 12:112 Page 4 of 19
http://www.molecular-cancer.com/content/12/1/112When co-cultured with PC3 cells, HS5 bone stromal
cells (Figure 1C’-C”; green fluorescence) lost their ordered
cellular phenotype becoming loosely aggregated, a charac-
teristic associated more readily with an invasive meta-
static phenotype. HS5 cells clearly integrated with PC3
cells (Figure 1C”; arrowheads) forming cell-cell contacts.
Interestingly, when plated with another PCa metastatic
cell line, DU145 cells, HS5 cells retained their characteris-
tic phenotype and rarely formed cell-cell contacts with
DU145 cells whose rounded phenotype was maintained in
this co-culture (Figure 1D-D’; arrowheads). These results
suggest that HS5 cells have a high affinity to interact
specifically with bone derived metastatic cells.
Endogenous protein expression of α6β1 integrin
Previously, we have shown that in comparison to the
prostate epithelial cell line RWPE-1, PC3 cells in 3D
displayed an up-regulation in the total protein expression
of β1 integrin and a down-regulation of α6 integrin ex-
pression [4]. Following on from these findings we then
wanted to establish whether HS5 and tumour-stromal
co-cultures expressed integrin subunits α6 and β1. Densi-
tometric results revealed that similar to expression levels
previously reported for prostate epithelial RWPE1 cells
[4], HS5 cells expressed minimal levels of β1 integrin
with a two fold increase in total protein observed by day
9 in culture (Figure 1E). Consistent with the addition of
PC3 cells that are known to express high levels of β1 in-
tegrin, tumour-stromal co-cultures displayed a signifi-
cantly higher level of total β1 integrin protein levels across
all days in culture with a 9 fold increase evident by day 9
(Figure 1E). HS5 cells expressed minimal but detectable
levels of α6 integrin at days 6 and 9 (Figure 1E). In com-
parison to HS5 cells, there was a slight up-regulation of
α6 integrin expression in co-cultures with a 1.8 fold
increase apparent by day 9.
Beta 1 and α6 integrin expression on HS5 and PC3 cells
in co-culture
To further clarify the relative proportion of β1 and α6
integrin expression on the two different cell types in co-
culture, immunoassaying was undertaken at days 3, 6 and
9 and script analysis was employed. A similar proportion
of HS5 and PC3 cells expressed β1 integrin at day 3,
however at day 6 and 9, a significantly higher percentage
of PC3 cells were found to express β1 integrin in
comparison to HS5 cells (Figure 1G). Immunostaining
revealed that in comparison to HS5 cells (Figure 1F’;
STRO-1 positive), PC3 cells expressed β1 integrin at
higher intensities (Figure 1F-F”). Alternatively, the propor-
tion of cells expressing α6 integrin at days 3 and 6 were
similar. By day 9 the percentage of HS5 cells expressing α6
significantly increased in comparison to PC3 cells (Figure 1I).
Immunostaining revealed that while the percentage of cellsincreased, the general intensity of the α6 stain was simi-
lar on both PC3 and HS5 cells (Figure 1H-H”).
These results suggest that in tumour-stromal co-cultures,
a higher percentage of PC3 cells express β1 at higher inten-
sities while α6 integrin is expressed more consistently by
HS5 cells.
Integrin α6β1 inhibition leads to phenotypic and
morphological alterations
When PC3 cells were grown in the presence of the α6
blocking antibody (GoH3), there was little difference in the
overall phenotypic appearance of these cells (Figure 2A’)
when compared to their IgG controls (Figure 2A). In the
presence of β1 (P5B2) or a combination of the α6 and β1
blocking antibodies, PC3 cells displayed a remarkable
change in phenotypic structure, losing their stellate
morphology, and assuming a more grape-like appear-
ance (Figure 2A’). To investigate further the characteristics
of cell junction formation in PC3 cells we carried out im-
munostaining for F-actin at day 9. PC3 cells treated with
α6β1 inhibitors formed rounded grape-like structures with
robust cell-cell contacts (Figure 1A”) although no acinar
formation or polarisation was evident.
In the presence of α6 blocking antibodies, HS5 cells
(Figure 2B’) displayed a similar phenotypic morphology
to that of IgG controls (Figure 2B), although at times the
boundaries of the spheroid regions were more clearly
defined (Figure 2B). In the presence of β1 blocking anti-
bodies, HS5 cells also displayed a remarkable change
in phenotypic structure, assuming a well organised and
rounded appearance (Figure 2B’). F-actin staining of HS5
cells in these conditions revealed a polarised spheroid
structure complete with acinar formation (Figure 2B”;
arrowhead).
When cultured together, 3D tumour-stromal cultures
displayed disorganised clusters of stellate structures
(Figure 2C), with a similar phenotype observed in the
presence of α6 blocking antibodies (Figure 2C’). In the
presence of β1 or combination α6β1 blocking antibodies,
tumour-stromal co-cultures also displayed a reversion
of phenotype marked by the presence of rounded polarised
masses with additional smaller grape-like structures situ-
ated around the periphery (Figure 2C’; arrowheads). F-actin
staining of α6β1 inhibited co-cultures revealed that HS5
stromal cells no longer formed acinar as seen in mono-
cultures. Alternatively, they populated the outer regions
of the spheroid masses (Figure 2C”; filled arrowheads),
while PC3 positive cells populated the inner regions of
the spheroid with no acinar formation evident (Figure 2C”;
unfilled arrowhead).
These results suggest that β1 integrin can modulate
cell-cell contacts and cell-ECM contacts, altering pheno-
typic morphology in monocultures that are reflective of an
epithelial-like reversion. The degree of control exhibited
Figure 2 (See legend on next page.)
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Figure 2 Integrins mediate morphology and invasive qualities of monocultured and co-cultured cells. (A-A”) PC3 cells grown in the
presence or absence of either α6, β1 or both inhibiting antibodies. (A”) F-actin staining of PC3 cells in 3D culture. (B-B”) HS5 cells grown in the
presence or absence of either α6, β1 or both inhibiting antibodies. (B”) F-actin staining of HS5 cells grown in the presence of both α6 and β1
inhibiting antibodies with acini formation (filled arrowhead). (C-C”) Co-cultured cells grown in the presence or absence of either α6, β1 or both
inhibiting antibodies. (C”) In the presence of both α6 and β1 inhibiting antibodies, HS5 cells (STRO-1; green fluorescence) localised to the outer
edge (filled arrowhead), while the PC3 cells (Cell Mask blue positive; STRO-1 negative) resided in the centre of the spheroid mass (unfilled
arrowhead). (D) Quantification of the number of proliferating cells in PC3, HS5 and co-cultured cells over a 9 day period. (E) Quantification of the
percentage of HS5 and PC3 cells proliferating in co-culture over a 9 day period. (F-F’) EDU labelling (red fluorescence) of HS5 (STRO-1 positive;
green fluorescence) and PC3 cells (CellMask blue positive; STRO-1 negative) in co-culture at day 9. (G) Quantification of the number of cells to
invade in the presence and absence of integrin inhibitors for PC3, HS5 and co-cultured cells. (H). Quantification of the percentage of invaded HS5
and PC3 cells in co-culture. (**p < 0.01, ***p < 0.001). Error bars denote S.E.M. Scale bars = 40 μm.
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tures and co-cultures as evidenced by the lack of polarisa-
tion and acinar formation in HS5 cells in the presence of
PC3 cells, suggestive of a more invasive phenotype.
Proliferation rates in monocultures vs co-cultures
Using an Alamar Blue based proliferation assay conducted
over a 9 day period, we were able to determine prolifera-
tion rates in 3D for both monocultures and tumour-
stromal co-cultures.
Consistent with previous findings [29], in comparison
to monocultures of HS5 or PC3 cells, tumour-stromal
co-cultures exhibited significantly higher proliferation rates
at days 6 and 9 (Figure 2D). To further explore the prolifer-
ative behaviour of PC3 and HS5 cells when co-cultured in
3D, an EDU click-it assay was performed to assess the rela-
tive contribution of each cell type (Figure 2F-F”). At day 3,
in comparison to HS5 cells, PC3 cells proliferated at signifi-
cantly higher rates, similar to proliferation rates reported
for monocultures (Figure 2E). By day 6, both PC3 and HS5
cells were proliferating at similar rates (Figure 2E, F-F”).
These results suggest that in the presence of PC3 cells, the
proliferative behaviour of HS5 cells is altered when com-
pared to their monoculture counterparts.
Beta 1 integrin modulates invasive capacity in co-cultures
only in the presence of laminin
The ability of cells to metastasise to distal organs is
largely mediated by their ability to migrate and invade.
Thus we next wanted to ascertain whether there were
differences in invasive capacity between monocultures
versus tumour-stromal co-cultures and whether α6 and/or
β1 integrin may mediate this invasive behaviour. To in-
vestigate this we used transwell invasion assays in the
presence or absence of α6 and/or β1 function blocking
antibodies.
In agreement with previous reports [30], tumour-stromal
co-cultures were reproducibly more invasive than mono-
cultures of either HS5 or PC3 cells. These results were
observed whether in the presence of FBS or FBS and
laminin in the lower chamber wells (Figure 2G). All cul-
tures were observed to invade at significantly higherrates in the presence of laminin (Figure 2G). Inhibition
of α6 in PC3 cells significantly decreased their invasive
capacity while inhibition of β1 and a combination of
α6β1 abolished PC3 cells from invading through the
Matrigel and porous membrane (Figure 2G). These re-
sults suggest that both α6 and, to a greater degree, β1
integrin subunits positively mediate the invasive cap-
abilities of PC3 cells.
Inhibition of β1 in HS5 cells saw no significant differ-
ence in invasive capacity compared with IgG treated con-
trols (Figure 2G). Inhibition of α6 or α6β1 resulted in a
significant decrease in invasive capacity, indicating that
α6 positively controls invasion in this cell-line. The same
results were found when HS5 and PC3 cells were plated
together. Inhibition of α6 and a combination of α6β1 to
co-cultures saw a consistent decrease in invasive capacity
(Figure 2G). However, effects concerning inhibition of β1
on co-cultures were only evident in the presence of its
ligand, laminin (Figure 2G).
We next wanted to ascertain the relative contribution
of invading stromal and tumour cells in co-culture. To
investigate this, transwell invasion assays in the presence
or absence of α6 and/or β1 function blocking antibodies
with FBS and laminin in the lower chamber wells were
used. Following invasion, cells were fixed and each cell
type was visualised via staining for STRO-1 and cell mask
blue. Unlike their monoculture counterparts, when HS5
cells were in the presence of PC3 cells, their invasive
capacity was found to equal that of PC3 cells with 52.3%
of invaded cells being HS5 positive (Figure 2H). As
expected, inhibition of integrin α6, β1 or combination
α6β1 resulted in significantly higher number of HS5 cells
invading in comparison to PC3 cells (Figure 2H). In
monocultures, PC3 cells were nearly completely abolished
but in the presence of HS5 cells, a relatively high percent-
age of PC3 cells (~ 35%) continued to invade in the pres-
ence of β1 or combination α6β1 inhibitors (Figure 2H).
Collectively, these proliferation and invasion results sug-
gest that with the addition of tumour cells, stromal cell
behaviour is altered; encouraging increased migratory
behaviour and invasiveness. Moreover, in co-cultures,
α6 and β1 integrins do not mediate these cellular processes
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that stromal cells may play a protective role against
inhibitory elements that may otherwise reduce tumour
genesis.
Alpha 6 and β1 integrins mediate EMT marker expression
Previously it has been shown that inhibiting α6 or β1 in-
tegrin activity can induce a re-expression of E-Cadherin
in metastatic PCa cell-lines [31]. We then investigated
whether α6 or β1 integrin controls the structural homeo-
stasis and expression of important EMT markers including
E-Cadherin and N-Cadherin in both monocultures and
tumour-stromal co-cultures. Using immunocytochemistry
and western blotting techniques, 3D assays were conductedFigure 3 The expression of E-Cadherin in the presence of integrin inhib
expression in RWPE1, PC3, HS5 and co-cultured cells (PC3 + HS5) in the prese
in PC3 cells. (B’) Immunostaining of E-Cadherin in PC3 cells in the presence o
(D) Expression of E-Cadherin in HS5 cells in the presence of α6 and β1 inhibit
expressed by HS5 cells (STRO-1; filled arrowhead) in co-culture. (F-F’) Expressi
inhibitors saw an up-regulation on HS5 cells (STRO-1; filled arrowheads) and a
Scale bars = 40 μm.to ascertain EMT expression rates for monocultures
including PC3, HS5 and RWPE-1 cells and tumour-
stromal co-cultures in the presence or absence of in-
tegrin function blocking antibodies.
Western blot analysis revealed that the prostate epi-
thelial cell line, RWPE-1, expressed high protein levels
of E-Cadherin that were not altered in the presence of
either α6 or β1 integrin blocking antibodies (Figure 3A).
In agreement with our previous findings [4], PC3 cells
did not express detectable levels of E-Cadherin as con-
firmed by western (Figure 3A) and immunostaining
(Figure 3B). In the presence of α6 blocking antibodies,
E-Cadherin expression on PC3 cells was slightly up-
regulated, while a 2 fold increase was observed in β1itors. (A) Western blot and densitometric analysis of E-Cadherin
nce and absence of integrin inhibitors. (B) Immunostaining of E-Cadherin
f α6 and β1 inhibitors. (C-C’) Immunostaining of E-Cadherin in HS5 cells.
ors. (E-E’) Immunostaining of E-Cadherin (red fluorescence) was primarily
on of E-Cadherin in co-cultured cells in the presence of α6 and β1
re-expression of E-Cadherin on PC3 cells (Cell Mask; unfilled arrowheads).
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ation α6β1 blocking assays (Figure 3A). These results
were further confirmed via immunostaining. In the pres-
ence of integrin inhibitors E-Cadherin expression was
clearly present on the membrane of PC3 cells, indicative
of a functional receptor (Figure 3B’).
Similar results were found for HS5 cells. Minimal pro-
tein levels of E-Cadherin were found in IgG controls as
confirmed by western (Figure 3A) and immunostaining
(Figure 3C-C’) results. In the presence of α6 blocking
antibodies, E-Cadherin expression on HS5 cells was
up-regulated, while a 3 fold increase was observed in
β1 blocking conditions and in combination α6β1 blocking
assays (Figure 3A). Immunostaining confirmed these
results with E-Cadherin clearly present on the membrane
of HS5 cells, indicative of a functional receptor (Figure 3D).
In tumour-stromal co-cultures, E-Cadherin expression
was up-regulated in IgG controls when compared to
monocultures of HS5 or PC3 cells (Figure 3A). Immuno-
staining revealed that expression was primarily present
on HS5 cells (Figure 3E-E’; filled arrowhead). In the
presence of α6 blocking antibodies, E-Cadherin protein
expression on co-cultured cells was slightly up-regulated,
while a 2 fold increase was observed in β1 and combin-
ation α6β1 blocking assays (Figure 3A). Immunostaining
further confirmed these results with E-Cadherin expres-
sion up-regulated on HS5 cells (Figure 3F-F’; filled arrow-
heads) and re-expressed on PC3 cells (Figure 3F’-F”; unfilled
arrowheads).
Collectively, these results confirm that α6, and to a
greater degree, the β1 integrin subunit, can mediate
E-Cadherin expression and control the structural homeo-
stasis of these cells in both mono and co-culture assays.
RWPE-1 cells exhibited minimal N-Cadherin and in the
presence of either β1 or in combination α6β1 blocking
assays, N-Cadherin expression was further down-regulated
(Figure 4A). HS5 cells expressed minimal levels of N-
Cadherin as evidenced by western (Figure 4A) and immu-
nostaining (Figure 4B-B’) with no alterations observed in
the presence of integrin function blocking antibodies
(Figure 4A). Alternatively, PC3 cells expressed detect-
able levels of N-Cadherin and in the presence of α6, β1
or a combination of both integrin inhibitors, expression
was up-regulated 3 fold (Figure 4A). Immunostaining re-
vealed a redistribution of N-Cadherin expression on PC3
cells from primarily membrane bound on IgG controls
(Figure 4C) to cytoplasmic and nucleic on cells treated
with α6, β1 or α6β1 inhibitors (Figure 4C’-C”), indica-
tive of a non-functional receptor. These results suggest
that both α6 and β1 integrin subunits are vital to the
functional presentation of N-Cadherin to the membrane
in PC3 cells.
In co-cultures, N-Cadherin expression was present as
observed by both western (Figure 4A) and immunostaining(Figure 4D-D”). It became evident that once plated with
PC3 cells, HS5 cells re-expressed N-Cadherin that was
clearly present on the membrane (Figure 4D’-D”; arrow-
heads). Co-cultures treated with α6, β1 or a combination
of α6β1 inhibitors resulted in an up-regulation of N-
Cadherin expression (Figure 4A). In these conditions, HS5
cells continued to re-express membranous N-Cadherin
(Figure 4E-E’; arrowheads). Moreover, unlike their mono-
cultured counterparts, PC3 cells in co-culture were found
to express membranous N-Cadherin, suggesting that in the
presence of HS5 cells, integrin inhibition no longer
rendered N-Cadherin non-functional. These results sug-
gest that HS5s may provide a “protective” mechanism
that encourages the retention of functional mesenchymal
properties known to encourage tumour progression.
We next wanted to ascertain whether the up-regulation
of N-Cadherin expression in HS5 cells was due to soluble
factors excreted by PC3 cells in co-culture assays. To in-
vestigate this HS5 cells were treated with PC3 treated
media over a 9 day time-course. In comparison to un-
treated HS5 cells (Figure 4F), HS5 cells grown in PC3
treated media lost their organised phenotype by day 6 in
culture and formed irregular shaped clusters with stellate
radiating tubular processes, consistent with a metastatic
cell-line (Figure 4F’). These results were PC3 specific as
HS5 cells grown in embryonic fibroblastic (3T3) treated
media (Figure 4F”) were unaffected. Moreover, western re-
sults confirmed an up-regulation of N-Cadherin expres-
sion in HS5 cells when treated with PC3 treated media
with a 3 and 2.4 fold increase at days 6 and 9, respectively
(Figure 4G).
Beta 1 integrin mediates vimentin expression in 3D
monocultures
Consistent with an epithelial phenotype, RWPE1 cells
did not express detectable levels of vimentin (Figure 5A).
Alternatively, invasive (PC3) and mesenchymal (HS5) cell
types expressed vimentin with similar levels recorded in
co-culture assays (Figure 5A). In the presence of α6
blocking antibodies, expression of vimentin was not altered
on PC3, HS5 or co-cultured cells. Alternatively, in the
presence of β1 blocking antibodies, vimentin was up-
regulated 2 fold in PC3 cells, while there was minimal
effect on total protein expression found in monocultured
HS5 cells (0.73) or in co-cultures (0.78; Figure 5A). Similar
results were found in cells grown in the presence of α6β1
inhibitors (Figure 5A).
Immunostaining of monocultured PC3 cells revealed
that in IgG controls, vimentin expression was evident
within the cytoplasm and cytosol of the cell (Figure 5B),
indicative of a functional intermediate filament (IF) pro-
tein. Alternatively, when treated with β1 or combination
α6β1 inhibitors, vimentin expression was redistributed
to the membrane of PC3 cells (Figure 5B’). These results
Figure 4 The expression of N-Cadherin in the presence of integrin inhibitors. (A) Western blot and densitometric analysis of N-Cadherin
expression in RWPE1, PC3, HS5 and co-cultured cells (PC3 + HS5) in the presence and absence of integrin inhibitors. Dashed line indicates
samples taken from a separate membrane. (B-B’) Immunostaining of N-Cadherin in HS5 and (C) PC3 cells. (C’) Immunostaining of N-Cadherin in
PC3 cells in the presence of α6 and β1 inhibitors. (D-D”) Expression of N-Cadherin in co-cultures, in the presence of PC3 cells, N-Cadherin
expression was evident on HS5 cells (STRO-1; unfilled arrowheads). (E-E’) In the presence of α6 and β1 inhibitors, HS5 cells (STRO-1; unfilled
arrowheads) continued to express N-Cadherin. (F-F”) DIC image of HS5 cells treated with standard media, PC3-treated media or 3T3-treated
media. (G) Western Blot and densitometric anaylsis of N-Cadherin expression in HS5 cells using standard, PC3-treated and 3T3-treated media over
a 9 day period. Scale bar = 40 μm.
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Figure 5 The expression of vimentin in the presence of integrin inhibitors. (A) Western blot and densitometric analysis of vimentin
expression in RWPE1, PC3, HS5 and co-cultured cells (PC3 + HS5) in the presence and absence of integrin inhibitors. (B-B’) Immunostaining of
vimentin in PC3 cells under (B) control and (B’) β1 inhibitor conditions where vimentin was re-distributed to the membrane (unfilled arrowhead).
(C-C’) Expression of vimentin in co-cultures. Vimentin was present in the cytoplasm of HS5 (STRO-1; filled arrowheads) and PC3 (Cell Mask;
unfilled arrowheads) cells. (D-E’) In the presence of α6 or β1 inhibitors, HS5 (STRO-1; filled arrowheads) and PC3 (Cell Mask; unfilled arrowheads)
cells continued to express vimentin in the cytoplasm. Scale bars = 40 μm.
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volved in maintaining the functional localisation of this
receptor to the cytosol of the cell.
In HS5 cells, vimentin distribution remained within
the cytoplasm and cytosol of the cell and this distribu-
tion remained unaltered in the presence of any integrin
inhibition parameters (results not shown). Similarly, when
co-cultured, HS5 and PC3 cells retained a distribution pat-
tern consistent with a functional IF receptor (Figure 5C-C’;
filled arrowhead (HS5), unfilled arrowheads (PC3)). More-
over, in co-cultures, PC3 cells were found to express
functional cytosolic vimentin in the presence of β1 or
combination α6β1 inhibitors (Figure 5D-E’; filled arrow-
head (HS5), unfilled arrowheads (PC3)). These results
provide further evidence that HS5s in this model helpto retain mesenchymal properties known to encourage
tumourgenesis.
Alpha 6 and β1 integrins mediate chemokine CXCR7
receptor expression in tumour-stromal co-cultures
Previously, we have found that CXCR4 chemokine recep-
tors are highly expressed on the stellate processes exhibited
by PC3 cells in 3D culture [4]. Following on from these
results, we next wanted to ascertain the expression rates
of another important chemokine receptor CXCR7 and
whether α6 and/or β1 integrins mediate the expression
of these receptors.
In 3D, PC3 cells consistently expressed CXCR7 as
evidenced by western (Figure 6A) and immunostaining
(Figure 6B). In comparison to IgG controls, (Figure 6A; B),
Figure 6 The expression of CXCR7 in the presence of α6 and β1 integrin inhibitors. (A) Western blot and densitometric analysis of CXCR7
expression in RWPE1, PC3, HS5 and co-cultured cells (PC3 + HS5). (B) Immunostaining of CXCR7 expression in PC3 cells in the presence of IgG
control antibodies and (C) α6 and β1 inhibitors. (D) Immunostaining of CXCR7 expression in HS5 cells. (E-E’) Immunostaining of CXCR7 in co-cultures
where HS5 cells (STRO-1) were found to re-express CXCR7 (unfilled arrowheads) at similar levels to that found on PC3 cells (filled arrowhead). (F-F’) In
co-cultures, HS5 (STRO-1; unfilled arrowheads) and PC3 cells (Cell Mask; filled arrowheads) continued to express CXCR7 in the presence of α6 inhibitors.
(G-G’) In the presence of α6 and β1 inhibitors, HS5 cells (STRO-1; unfilled arrowheads) continued to express CXCR7 at higher levels than found on PC3
cells (filled arrowhead). (H) Western blot and densitometric analysis of CXCR7 expression in HS5 cells using standard, PC3-treated, and 3T3-treated
media over a 9 day period. Scale bars = 40 μm.
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the presence of β1 or a combination of α6β1integrin
inhibitors, while inhibition of α6 saw no change
(Figure 6A; C). These results suggest that on mono-
cultured PC3 cells, CXCR7 expression is positively medi-
ated by β1 integrin.Prostate epithelial cell-line RWPE-1 did not express
detectable levels of CXCR7 (Figure 6A), nor did mono-
cultured HS5 cells (Figure 6A, D). However, when co-
cultured, HS5 cells were found to re-express CXCR7
(Figure 6E-E’; empty arrowheads) at levels similar to
that found on PC3 cells (Figure 6E-E’; filled arrowhead).
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combination of inhibitor antibodies, CXCR7 expression
was consistently down-regulated (Figure 6A). Dissimilar
to monocultured PC3 cells, in co-cultures, α6 was now
found to positively mediate CXCR7 expression.
Immunostaining revealed that in α6 inhibited co-cultures
both PC3 (Figure 6F-F’; filled arrowheads) and HS5 cells
(Figure 6F-F’; unfilled arrowheads) continued to express
CXCR7 at similar levels, however in β1 and α6β1 inhibi-
tor assays, CXCR7 was predominately expressed by HS5
cells (Figure 6G-G’; unfilled arrowheads), with little ex-
pression noted on PC3 cells (Figure 6G-G’; filled arrow-
heads). These results suggest that similar to monoculture
conditions, β1 integrin continues to mediate CXCR7 ex-
pression on PC3 cells in co-culture.
To verify whether soluble or contact mediated factors
associated with PC3 cells could regulate the re-expression
of CXCR7 on HS5 cells, HS5 cells were grown over a
9 day time-course in the presence or absence of PC3
treated media. When HS5 cells were challenged with
PC3 or 3T3 treated media, no evident alteration in
CXCR7 expression was found (Figure 6H). Furthermore,
CXCR7 expression was barely detectable by day 9 in cul-
ture. These results suggest that soluble factors excreted by
PC3 cells do not mediate up-regulation of CXCR7. It is
likely that other factors including endocrine cell-cell and
cell-ECM contact mediation may regulate endogenous
up-regulation in co-cultured HS5 cells.
Discussion
In agreement with previous findings [6,29], our results
suggest that addition of stromal cells to metastatic PCa
cells in 3D culture can accelerate cancer growth and inva-
sion. Through soluble and contact mediated mechanisms,
PC3 and HS5 cells reciprocally interact to facilitate
tumour growth by up-regulating EMT markers and che-
mokine receptors known to mediate bone metastatic
dissemination. In addition, we demonstrate for the first
time that both α6 and β1 integrins mediate invasion,
EMT protein expression and phenotypic homeostasis in
these co-cultures.
Morphological changes in HS5 cells in co-culture
Utilising both DIC and fluorescence microscopy we and
others [3,4] have confirmed that when grown in Matrigel
the PCa cell-line, PC3 formed structures consistent with
an invasive phenotype while HS5 cells formed structures
consistent with a non-malignant phenotype . When cultured
together, the phenotypic characteristics of monocultured
HS5 cells are altered becoming a highly disorganised ar-
rangement of cells characterised by long chains of stellate
processes, consistent with a highly invasive phenotype. In
co-cultures, both cell types formed cell-cell contacts.
These results coincide with others who have shown thatcancer-stromal interactions can lead to spontaneous
fusion between the two cell types [32].
When co-cultured with another metastatic cell line,
DU145, HS5 cells were not seen to alter in phenotype
with both cell types forming isolated cell specific masses.
Similar results have been shown where bone derived
metastatic cancer cells adhere more avidly to bone-
marrow derived endothelial cells in comparison to endothe-
lial cells harvested from non-target organs [33]. Our results
are consistent with the idea that tumour-stromal micro-
environments are highly niche specific. Both PC3 and HS5
cells are derived from the bone micro-environment where
similar ECM molecules and gene expression programs
are established. Alternatively, DU145 cells are derived
from the brain in the central nervous system where ECM
parameters are very different [34].Inhibition of β1 integrin results in phenotypic reversion
To the best of our knowledge, this is the first time that
the effect of α6 and β1 integrin function-blocking anti-
bodies has been tested against tumour-stromal co-cultures
in 3D. Here we have shown that in the presence of antibody
inhibitors for β1 integrin, PC3, HS5 and tumour-stromal
cell co-cultures all displayed alterations in their phenotypic
appearance. Both PC3 and tumour-stromal co-cultures dis-
played a partial reversion with no acinar formation present,
while HS5 cells cultured alone displayed a drastic reversion
to a complete epithelial type, marked with prominent acinar
formation. Similar results have been reported for a highly
metastatic PCa cell-line M12; acinar formation was evident
after inhibition of either β1 or α6 integrin subunits [31]. In
contrast, we found that inhibition of α6 did not clearly me-
diate obvious phenotypic changes in these cell-lines and in
part could be explained by the promiscuous nature of the
β1 subunit. It is known that the β1 subunit has over 8
known alpha subunit partners with both α2β1 and α5β1
actively implicated in the tumour-bone stromal processes
[12,13]. Therefore in our β1 inhibitor assays, it is assumed
that we are in part preventing the activation of all these
alpha subunits. Alternatively when we inhibit the α6 sub-
unit, it is highly likely that the partnering of the β1 subunit
to other known alpha subunits is altered and possibly en-
courages activation of both α2 and α5 subunits. As such,
understanding how the inhibition and/or activation of
one subunit can affect the coupling of other known
heterodimer partners in tumour development will be
imperative in establishing therapeutics targets and is the
work of future studies.
Noteworthy is the inability of β1 inhibition to com-
pletely revert the phenotype of HS5 cells once co-cultured
with PC3 cells. These results are consistent with the idea
of rapid phenotypic plasticity where human bone stromal
cells undergo permanent cytogenetic and gene expression
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of metastatic cells [5].
Co-cultures display altered invasion and proliferation rates
Consistent with previous findings [29,30] co-cultured cells
proliferated and invaded at significantly higher rates in
comparison to PC3 or HS5 cells plated in isolation. Of
interest was the apparent up-regulation of proliferation
rates following 3 days in culture for mono and co-cultured
cells. This time-course correlates with progressive changes
in cell-cell interactions and various genes involved in
lipid/steroid metabolism, adhesion, ECM turnover and
development/differentiation known to occur in a 3D
in vitro micro-environment [3]. It is therefore likely that
the changes noted in proliferative rates were a result of
interactions and cross-talk between growth factors and
hormones being released within the enhanced paracrine
network of the co-culture structure. This would explain
in part studies [35] that have reported no apparent dif-
ferences in proliferation rates in co-cultures of PC3 and
HS5 cells using 2D monolayer assays where appropriate
cell-cell and cell-ECM contacts are not formed.
Supported by recent in vitro studies [31,36] and knock-
out strategies in transgenic mouse tumour models [37],
we have shown that integrins can control tumour growth.
Collectively, our results demonstrate that both α6 and β1
integrins mediate invasion of monocultured and tumour-
stromal co-cultured cells in 3D. Similar to previous results
regarding integrins α2β1 and α5β1 [12,13], this is the
first report to establish that α6β1 can actively facilitate
tumour-bone stromal interactions in vitro. In monocul-
tures, α6 is highly influential in positively mediating in-
vasion in HS5 cells, while both β1 and α6 integrins
positively mediate these functions in PC3 cells. When
these cell lines are cultured together however, the de-
gree to which integrins mediate invasion are attenuated,
favouring a more tumourgenic niche. These results could
in part explain why certain integrin therapeutics have been
less than convincing in clinical trials [38]. Similar to find-
ings utilising perineural invasion models in PCa [39], we
have also shown that co-cultures display an increased
dependency on the ECM component, laminin, during
invasion. Establishing a comprehensive understanding
of the increased laminin dependent invasion of both tumour
and stromal cells may provide a further framework for
developing pertinent biomarkers or targeted therapies.
Alterations in endogenous expression of EMT markers
and chemokine receptors in co-culture
Our results regarding endogenous expression of EMT
markers and chemokine receptors in monocultured and
co-cultured cells is summarised in Figure 7A. In monocul-
tures, PC3 cells exhibit profiles consistent with a highly
metastatic phenotype, while HS5 cells expressed profilesconsistent with a non-cancerous mesenchymal phenotype.
When co-cultured with PC3 cells, HS5 cells re-expressed
N-Cadherin and CXCR7, proteins that are known to ac-
celerate cancer growth at the primary tumour site and
support metastatic colonisation in distal organs [40,41].
One of the hallmarks of EMT is the loss of the E-Cadherin,
and the concomitant increase in expression of the mesen-
chymal cell-cell adhesion molecule N-Cadherin, a process
also known as the Cadherin switch [42,43], which can pro-
voke cell migration and invasion in breast cancer cells
[44,45]. Here we report for the first time that soluble
factors excreted by PC3 cells can alone mediate the re-
expression of N-Cadherin in HS5 cells. Functionally, this
up-regulation is known to cause a change in the adhesive
properties of cells and in the case of tumour cells, lose
their affinity for their epithelial neighbours, a mechanism
that encourages metastatic seeding and colonisation [43].
Further studies are now needed to verify the identity of
these soluble molecules responsible for this up-regulation
in N-Cadherin and the direct functional consequences
of these alterations. A large number of growth factors
and their activated signal transduction pathways are known
to provoke the Cadherin switch including transforming
growth factor β (TGFβ; [46]), hepatocyte growth factor
(HGF; [47]), insulin-like growth factor (IGF; [48]), fibro-
blast growth factor (FGF; [49]) and Notch signalling [50].
In addition to soluble factors, there are a plethora of
contact mediated variables that could account for the
re-expression of CXCR7 in co-cultured HS5 cells. One
possibility is the modulation of chemokine receptors
through hypoxic conditions, which is known to induce
cancer cell expression of c-Met, the bona fide receptor
of HGF, and CXCR4, the signalling receptor of the chemo-
kine CXCL12 (SDF1), and further stimulate cancer cell
migration and dissemination [51,52].
Alpha 6 and β1 integrins mediate EMT proteins and
CXCR7 expression in co-cultures
We report here that both α6 and β1 integrin subunits can
influence expression rates of important EMT markers
(E-Cadherin, N-Cadherin and vimentin) and chemokine
receptor CXCR7 in both monocultured and co-culture
assays. Our results regarding integrin mediated changes
in these proteins is summarised in Figure 7B. Taken to-
gether, our results suggest that inhibition of α6 and β1
integrins can mediate a MET program in monocultured
cells (See Figure 7B), while integrin mediation in co-
cultures is clearly altered with the re-establishment of
functional N-Cadherin and vimentin expression on PC3
cells, consistent with an EMT program. These results
suggest that HS5 cells may play a role in maintaining
functional homeostasis of N-Cadherin and vimentin ex-
pression on PC3 cells and as such maintain a higher inci-
dence of mesenchymal attributes. These results highlight
Figure 7 Summary of endogenous and integrin mediated expression profiles of monocultured and co-cultured cells. (A) Summary of
endogenous protein expression in PC3, HS5 and co-culture models. (B) Summary of integrin mediated protein expression in monocultures of
PC3, HS5 and co-culture models.
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effectiveness of integrin centred therapeutics.
Of interest was the clear redistribution of N-Cadherin
and vimentin in monocultured PC3 cells when treated with
β1 inhibitors. The distribution patterns of these markers
were indicative of a reduced junctional and IF protein,
respectively. However, the degree to which E-Cadherin
in these cells may then activate the Cadherin-catenin
complex to mediate the metastatic phenotype needs fur-
ther clarification. Previous studies have shown that with
a decrease in junctional E-Cadherin protein, catenins be-
come localized to the nucleus where they activate the
transcription of proto-oncogenes, stimulating mitosis [53].
Conclusions
Using 3D tumour-stromal co-cultures we have shown
that the addition of bone derived stromal cells to meta-
static PCa cells helps support tumour growth and protects
PC3 cells from integrin mediated alterations associated
with MET. Reciprocally, we have also found that the
addition of PC3 cells results in significant up-regulation
of invasive and proliferative behaviour in addition to re-
expression of N-Cadherin and CXCR7 on HS5 cells.
Further studies now need to evaluate the cross talk that
occurs between these two compartments on a system-
atic, cellular and molecular basis and will likely lead to
identification of new targets for therapy.
Materials and methods
PCa Cell Lines
Cell lines were purchased from ATCC and were passaged
for less than 4 weeks during any given assay performed
for this paper. ATCC routinely use COI for interspecies
identification and STR analysis (DNA profiling) for intra-
species identification for all cell-lines. The PCa cell lines
(DU145, PC3), Bone Stromal Cell-line (HS5) and the 3T3
fibroblast cell-line were maintained in RPMI-1640 (Sigma-
Aldrich), supplemented with 10% fetal bovine serum (FBS,
Gibco) and the prostate epithelial cell-line RWPE-1 was
maintained in Keratinocyte Serum Free Media (KSFM,
Gibco) supplemented with 20 mg/mL bovine pituitary ex-
tract (BPE) and 0.2 ng/mL epidermal growth factor (EGF).
All cells were propagated in standard cell culture condi-
tions (5% CO2, 37°C) in cell cultured treated T75 Flasks
(Flalcon). Media was replenished every 3 days. Once cells
had reached 80-90% confluency, cells were replated (1/10)
in T75 flasks. After 10-12 passages, cells were discarded.
3D cultures and tumour-stromal co-cultures
For miniaturised 3D cultures, 45 μl phenol red free (PRF)
Matrigel™/culture medium (70%: BD Biosciences) was
added to 96 well plates and polymerised at 37°C with 5%
CO2 for 1 hr. Cultures of cell-lines including RWPE-1,
PC3, DU145 and HS5 cells were seeded at ~5000 cells perwell and co-cultures containing both PC3 and HS5 cells
were plated together at ~2500 cells each (1:1 ratio) per
well and maintained in standard culture conditions. Media
was carefully removed and replenished every 3 days. Cul-
tures were maintained for up to 9 days.
3D bulk cultures for protein extraction
Protein extraction for western blotting was obtained from
3D Matrigel cultures grown in 12-well plates. For 3D cul-
tures, 450 μl PRF Matrigel™/culture medium (70%: BD
Biosciences) was added per well and allowed to polymerise
at 37°C with 5% CO2 for 1 hr. Single cell cultures were
then seeded at ~10000 cells per well while co-cultures
containing HS5 and PC3 cells were plated at ~5000 cells
each (1:1 ratio) per well and media was replenished every
three days. After 3, 6 and 9 days in culture, 3D bulk cul-
tures were extracted using Cell Recovery Solution (CRS:
BD Biosciences) as per the manufacturer’s instructions.
Cell pellets were then lysed and western blotting tech-
niques were carried out.
Integrin α6 and β1 inhibition assays
In order to block α6 or β1 integrin subunits, well
established functional blocking antibodies were diluted
(1.5 μg/mL) directly into the 3D matrix as follows: 1. α6:
GoH3 (R&D Systems), 2. β1: P5B2 (R&D systems), 3. α6
and β1 and 4. IgG isotope controls (R&D Systems). Cells
were then seeded and grown for 9 days in culture in
miniaturised 96 well or a bulk 12 well plate format.
Functional blocking antibodies and IgG isotope controls
were replaced during media changes every 3 days at
1.5 μg/mL concentration. Miniaturised 3D cell cultures
were then washed and fixed with 4% paraformaldehyde
(PFA) and immunocytochemistry was undertaken. For
inhibition assays carried out in a 12 well format, cells
were extracted using CRS and western blotting tech-
niques were undertaken.
Western blotting
Protein was collected from cells at days 3, 6 and 9 from
bulk 3D cultures. Treated cells were lysed in ice-cold
RIPA buffer (75 mM TrisCl pH 8, 150 mM NaCl, 0.1%
SDS, 1% Triton-X-100, 0.5% deoxycholic acid) containing
protease inhibitors (Roche), incubated at 4°C for 30 mins
prior to centrifugation at 14,100 g for 20 mins to pellet
cell debris. The supernatants were then assayed for pro-
tein concentration using DC Protein Assay (Bio-Rad), and
equal amounts of protein were loaded onto SDS-PAGE
gels for electrophoresis. The protein was then transferred
to Polyvinylidene Fluoride (PVDF) membranes in transfer
buffer (25 mM Tris Base, 200 mM glycine containing
15% methanol) for 30 mins using a Bio-Rad Turbo-Blot
system. PVDF membranes were blocked using 5% non-
fat milk powder for 1 hr, washed with TBST and primary
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mouse anti-E-Cadherin (2 μg/mL, Invitrogen), anti-human
integrin α6/CD49f (1 μg/mL; R&D Systems), anti-human
integrin β1/CD29 (0.2 μg/mL; R&D Systems), goat anti-
human vimentin (0.2 μg/mL, R&D Systems), rabbit anti-
CXCR7 (0.2 μg/mL; Abcam) and anti-human N-Cadherin
(0.5 μg/mL, R&D Systems) applied overnight (O/N) at
4°C. Membranes were then washed and HRP-conjugated
secondary antibodies (Bio-Rad) applied for 1 hr at 4°C
prior to washing and imaging on a Versa Doc (Bio-Rad)
imaging station. Membranes were stripped and re-probed
for β-actin in the case of vimentin, CXCR7 and CXCR4,
whereas E-Cadherin, N-Cadherin and integrin α6, β1
membranes were directly probed for β-actin. Densito-
metric analysis was performed using Image Lab software
and expressed as a fold change in relation to loading
controls and normalised against β-actin.
Immunocytochemistry
Miniaturised 3D cultures of PCa cells (DU145, PC3,
RWPE-1, HS5) and co-cultures (HS5 + PC3) grown in
384 well format were washed (3 × 5 mins PBS) and fixed
with 4% PFA for 20 mins. For immunofluorescence la-
belling, cells were washed (3 × 5 mins PBS), permeabilised
and blocked O/N with 2% BSA, 0.1% Triton-X, 0.05%
TWEEN20 at 4°C. Cells were further washed (1 × 5mins
PBS/0.1%TX, 2 × 5 mins PBS) and the following primary
antibodies were applied O/N at 4°C in blocking buffer:
mouse anti-E-Cadherin (5 μg/mL, Invitrogen), anti-
human Integrin β1/CD29, Anti-human Integrin α6/GoH3,
Goat anti-human vimentin, anti-human N-Cadherin, mouse
anti-STRO-1 (5 μg/mL, R&D Systems) and mouse anti-
CXCR7 9C4 (5 μg/mL, MBL International). Cells were
washed with PBS (3 × 5 mins), incubated with appropriate
secondary antibodies (5 μg/mL 488 goat anti-mouse,
5 μg/mL 594 goat anti-rat, 5 μg/mL 594 goat anti-rabbit),
nuclear stain Hoechst (1/1000, Invitrogen), filamentous
actin stains: Texas Red Phalloidin or 488 Phalloidin (1/80,
Invitrogen) and Cell Mask Blue (1/500, Invitrogen) for
4 hrs at room temperature (R/T). Cells were washed then
imaged using PerkinElmer Opera™ Confocal Imager and
an Olympus IX-81 Scanning Confocal microscope.
Proliferation assays of mono and co-cultured 3D cells
To assess cell proliferation in mono and co-cultured 3D
cells, assays were performed in 384-well plates using Alamar
Blue reagent (Invitrogen). TC-treated Falcon 384-well plates
(BD Biosciences) were applied with 15 μl of 70% Matrigel
(diluted in cold SFM) and left to polymerise for 2 hrs at
37°C, 5% C02 and 95% humidity. Mono culture (HS5 or
PC3 cells) were plated at ~800 cells/well and co-cultures
(HS5 + PC3 cells) were plated at ~400 cells/well each to
make a total of ~800 cells/well in 50 μL complete medium
per well and left to adhere O/N at 37°C, 5% CO2 and 95%humidity. A baseline reading was taken 24 hours after
plating (Day 0), and readings were obtained on assay days
3, 6 and 9 through application of 5 μl Alamar Blue per
well, achieving a final concentration of 10% (v/v). After
addition of Alamar Blue cells were further incubated for
4 hrs at 37°C, 5% CO2 and 95% humidity, before plates
were read on the Envision Plate Reader (Perkin Elmer)
using fluorescence excitation/emission settings of 530 nm/
595 nm. To investigate the relative contribution of prolifer-
ating HS5 and PC3 cells in co-culture, cells were treated
with Click-iT EdU HCS 594 kit (Invitrogen) at days 3, 6
and 9 in culture. After incubation with the EdU compound
in serum free media (10 μM, 24 hr), cells were fixed with
PFA, washed (3×5 mins PBS) and a 594 fluorescent
azide solution (100 mM TrisCl pH 8.5, 0.75 mM CuSO4,
50 mM Fluorescent Azide, 75 mM Ascorbic Acid, Milli-Q
water) was applied O/N at 4°C in blocking buffer along
with STRO-1 (5 μg/mL, R&D Systems) antibody. The
following day a general cytoplasmic and nuclear stain
(Cell Mask Blue 1/1000 and 1.5 hrs, Invitrogen) and a
secondary antibody (5 μg/mL 488 goat anti-mouse) was ap-
plied for 4 hrs at R/T. Cells were finally washed (3×5 min
PBS) and imaged using an Olympus confocal and results
were analysed using Imaris volume and spots.
Transwell cell invasion assays
To investigate the role integrin α6 and β1 play in medi-
ating invasive cell behaviour, transwell cell invasion as-
says (Corning, polycarbonate, 8.0 μm pore size) were
employed. Two days prior to each invasion assay, PC3
and HS5 cells were seeded in 6 well plates at a density
of 500,000 cells/well and co-culture (PC3 + HS5) cells
were seeded together at a 1:1 ratio to a total 500, 000
cells/well and left to adhere O/N at 37°C, 5% C02 and
95% humidity. The following day, cultures were serum
starved for 16-24 hours in the presence of integrin function
blocking antibodies: 1.5 μg/mL of α6; GoH3, 1.5 μg/mL of
β1; P5B2, α6 and β1 and 1.5 μg/mL of mouse IgG isotope
controls. On the day of the assay, cells were harvested
with accutase and seeded at a density of ~150,000 cells
per transwell insert in a volume of 200 μl SFM with the
addition of integin inhibitors: 1. 1.5 μg/mL of α6; GoH3,
2. 1.5 μg/mL of β1; P5B2, 3. α6 and β1 or 4. 1.5 μg/mL
of mouse IgG isotope controls. Prior to seeding cells,
20 μl of GFR Matrigel (1:5 dilution/SFM) was applied to
the transwell insert and polymerised for 1 hr at 37°C,
5% CO2 and 95% humidity. The undersides of the
transwell inserts were then coated with 4 μg of laminin
(Invitrogen) to encourage attachment of migrated cells.
For coating, a 1 mg/mL laminin stock solution was diluted
1/12.5 in warmed PBS, and 50 μl of this solution was
dispensed onto each insert and left to evaporate at RT.
The inserts were then washed in PBS and equilibrated
in SFM for 1 hr at 37°C, 5% CO2 and 95% humidity
Windus et al. Molecular Cancer 2013, 12:112 Page 17 of 19
http://www.molecular-cancer.com/content/12/1/112before cells were seeded onto the prepared transwell
inserts. Following addition of cells, 600 μl SFM was added
to the lower chamber with or without 10% FBS or 10%
FBS + 30 μg/mL of laminin and the plates were incubated
at 37°C, 5% CO2 and 95% humidity for 32 hrs to allow for
cell invasion to occur.
Cell invasion was then quantified through staining with
crystal violet. Invaded cells were fixed with 100% Metha-
nol for 10 mins at -20°C, prior to application of crystal
violet staining mixture (0.5% crystal violet in 20% Metha-
nol) for 30 mins to allow visualisation of cells. The non-
invaded cells on the upper surface of the insert were
removed with a cotton swab, the inserts washed in puri-
fied water and left to air dry. Cell invasion was quanti-
fied using images obtained on the InCell 1000 (GE) and
processed by an automated script generated by InCell
Developer. Counts were averaged between 3 assay replicates.
To further quantify the relative proportion of invading
HS5 and PC3 cells in co-culture, experiments were re-
peated as outlined above and cell invasion was quanti-
fied through staining with primary antibody STRO-1
(5 μg/mL, R&D Systems) for 2 hrs at R/T followed by a
general cytoplasmic and nuclear stain (Cell Mask Blue
1/1000 and 1.5 hrs, Invitrogen) and a secondary anti-
body (5 μg/mL 488 goat anti-mouse) application for
2 hrs at R/T. Cells were finally washed (3×5 min PBS),
membrane inserts carefully removed from the transwells,
placed on a glass slide and imaged using an Olympus
confocal and results were analysed using Imaris volume
and spots.
HS5 cultures treated with PC3 and 3T3 conditioned media
For these assays, PC3 and 3T3 fibroblast cell-lines were
propagated in T75 flasks for a minimum of 48 hrs in
RPMI complete media and maintained at 37°C in standard
cell culture conditions (5% CO2, 37°C and 95% humidity).
Supernatant from PC3 and 3T3 cells was collected after
48 hrs from T75 flasks and directly transferred to 3D HS5
cells. HS5 cells were plated into 12 well plates on GFR
Matrigel and left to adhere O/N in standard culture
conditions before addition of PC3 and 3T3 conditioned
media. Supernatant was replenished every 2 days. HS5
cells were imaged via Differential Inference Contrast
(DIC) optics and processed for western analysis on days 3,
6 and 9 in culture.
Live and fixed cell imaging
All fixed cells were imaged using either a PerkinElmer
Opera™ Quadruple Excitation High Sensitivity Confocal
Cell Imager with a PerkinElmer 20/.75 water iris, or an
Olympus IX-81 Scanning Confocal microscope, with an
Olympus PlanNeo-FLUAR 40/1 oil iris for multiple z-plane
acquisition. Z-stacks of 160-180 z-planes with a step size of
0.4-0.8 μm were acquired with Olympus Fluoview Ver 1.7 bsoftware (Olympus). 3D reconstructions of z-stacks were
created in Imaris x64 Ver. 7 software (Bitplane Scientific
Solutions). All live cell imaging was undertaken on the
InCell 1000 (GE) Cell Imager using a GE 20/.75 air iris
or on an Olympus Cell-R using an Olympus PlanNeo-
FLUAR 20/.75 air iris. Images were compiled using
Adobe Photoshop CS4 without further nonlinear digital
manipulation.
Quantification procedures and statistical analysis
Cell invasion by counting the number of migrated cells
across 4 fields using ×20 magnification on the InCell
1000 (GE) and processed by an automated script generated
by InCell Developer software (GE). Alternatively, quantifi-
cation of the relative contribution of invaded PC3 and HS5
cells in co-culture was attained across 4 fields using ×40
magnification on an Olympus confocal and processed using
Imaris x64 Ver. 7 software (Bitplane Scientific Solutions)
volume and surface tool. Counts were averaged between
3 assay replicates. Densitometric analysis was performed
using Image Lab software and expressed as a fold change
in relation to loading controls and normalised against
β-actin. This programme uses volume rendering which is
a far more accurate measure of protein concentration as
opposed to simple pixel intensity. Proliferation assays
were quantified by KC4: Kineticalc for Windows (Version
3.4; Bio-Tek Instruments) and counts were averaged be-
tween 3 assay replicates. To quantify the relative contribu-
tion of proliferating PC3 and HS5 cells in co-culture and
relative contribution of β1 and α6 expression, images were
attained on the Olympus confocal (n = 10 per variable)
and analysed using Imaris x64 Ver. 7 software volume and
surface tool. Counts were averaged between 3 assay repli-
cates. Statistical analysis was carried out using Graph-Pad
Prism (Version 5) and statistical significance for all given
variables was tested using Kruskal-Wallis test and Dunn’s
Multiple Comparison test for post-hoc analysis.
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